Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.65 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.63 |
| ▸ | PDE1A | P54750 | 2/20 | 0.56 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.56 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16558010 | 0.95 | PDE5A (0.70) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL439392 | 0.88 | PDE5A (0.78) | PDE5APDE3BPDE3APDE1APDE1B | |
| Lodenafil SCHEMBL18416781 | 0.87 | PDE5A (0.78) | PDE5APDE3BPDE3APDE1APDE1B | |
| Mirodenafil SCHEMBL15481149 | 0.85 | PDE5A (0.80) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL23937339 | 0.85 | PDE5A (0.52) | PDE5APDE3BPDE3A | |
| SCHEMBL1423 | 0.83 | PDE5A (0.86) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL29282029 | 0.83 | PDE5A (0.76) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL1190 | 0.82 | PDE5A (0.90) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL31202702 | 0.82 | PDE5A (0.90) | PDE5APDE3BPDE3APDE1APDE1B | |
| SCHEMBL19254528 | 0.82 | PDE5A (0.78) | PDE5APDE3BPDE3APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372351-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2023-11-23 | — | — | US | disclosed |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2021-10-21 | — | — | US | disclosed |
| WO-2020030489-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2020-02-13 | — | — | WO | disclosed |
| US-20150320677-A1 | EFFERVESCENT TABLET FORMULATIONS OF DAPOXETINE AND A PDE5 INHIBITOR | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2015-11-12 | — | — | US | disclosed |
| US-20150320677-A1 | EFFERVESCENT TABLET FORMULATIONS OF DAPOXETINE AND A PDE5 INHIBITOR | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2015-11-12 | — | — | US | disclosed |
| US-20150231092-A1 | NOVEL EFFERVESCENT SACHET FORMULATIONS OF DAPOXETINE AND A PDE5 INHIBITOR | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2015-08-20 | — | — | US | disclosed |
| US-20150231092-A1 | NOVEL EFFERVESCENT SACHET FORMULATIONS OF DAPOXETINE AND A PDE5 INHIBITOR | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2015-08-20 | — | — | US | disclosed |
| US-20150216798-A1 | NOVEL ORALLY ADMINISTERED PHARMACEUTICAL FORMULATIONS | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2015-08-06 | — | — | US | disclosed |
| US-20150216798-A1 | NOVEL ORALLY ADMINISTERED PHARMACEUTICAL FORMULATIONS | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2015-08-06 | — | — | US | disclosed |
| US-20130123264-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISORDERS AND INTESTINAL CANCERS | Georgia Health Sciences University | 2013-05-16 | — | — | US | disclosed |
| US-20130123264-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISORDERS AND INTESTINAL CANCERS | Georgia Health Sciences University | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123264-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISORDERS AND INTESTINAL CANCERS | PRKG2, PDE5A, PRKG1 | PDE5A 2/4885PDE3B 6/4885PDE3A 5/4885 |
| US-20150216798-A1 | NOVEL ORALLY ADMINISTERED PHARMACEUTICAL FORMULATIONS | PDE5A, PDE12, PDE3A | PDE5A 1/4885PDE3B 5/4885PDE3A 3/4885 |
| US-20150320677-A1 | EFFERVESCENT TABLET FORMULATIONS OF DAPOXETINE AND A PDE5 INHIBITOR | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE3B 4/4885PDE3A 3/4885 |
| US-20230372351-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE3B 5/4885PDE3A 2/4885 |
| US-20150231092-A1 | NOVEL EFFERVESCENT SACHET FORMULATIONS OF DAPOXETINE AND A PDE5 INHIBITOR | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE3B 6/4885PDE3A 3/4885 |
| US-20210322413-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE6A, PDE3A | PDE5A 1/4885PDE3B 6/4885PDE3A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.